Cleveland-based Sator Therapeutics develops naturally occurring, non-pathogenic oncolytic viruses intended to selectively kill cancer cells in hard-to-treat tumors. Its preclinical platform combines a library of nearly 30 human enterovirus strains with systemic delivery, sequential dosing, companion diagnostics, and a patented dendritic-cell carrier. The company’s approach is protected by four issued U.S. patents and a Japanese patent, while its lead mesothelioma program advances toward formal clinical development.
Abeona Therapeutics IncAbeona Therapeutics is a commercial-stage biopharmaceutical company developing and delivering cell and gene therapies for serious diseases, with its Cleveland, Ohio facility serving as the commercial manufacturing site for ZEVASKYN®, approved in April 2025. The company combines ex vivo gene therapy and viral-vector expertise with a developing PSMA-targeted synthetic immune receptor T-cell therapy for advanced prostate cancer. Its fully integrated manufacturing model keeps critical production steps in-house, supporting supply and consistency for patients with rare disease.CLEVELAND, OH
Iovance Biotherapeutics, IncIovance Biotherapeutics develops and manufactures personalized tumor-infiltrating lymphocyte (TIL) cell therapies for people with cancer. Its 136,000-square-foot Iovance Cell Therapy Center in Philadelphia makes TIL therapy using proprietary processes, including a 22-day Gen 2 process; the company also markets Amtagvi and Proleukin.PHILADELPHIA, PA
AdaptimmuneAdaptimmune develops engineered T-cell receptor (TCR) therapies designed to direct the immune system against cancer, with a particular focus on solid tumors. Based in Oxfordshire, the company has built its platform over more than 15 years to identify cancer targets, enhance T-cell receptor affinity and screen candidates for potential off-target binding.541714PHILADELPHIA, PA
Facili Bio LLCFacili Bio LLC uses an AI-powered drug-discovery platform and proprietary computational biology to develop new cancer treatments. The company focuses on difficult areas of oncology, pairing research into patient-specific therapies with clinical studies intended to move promising discoveries toward patients.ALBANY, NY